{"id":68830,"date":"2026-06-24T23:42:30","date_gmt":"2026-06-24T15:42:30","guid":{"rendered":"https:\/\/flcube.com\/?p=68830"},"modified":"2026-06-24T23:42:34","modified_gmt":"2026-06-24T15:42:34","slug":"abb-bio-tech-secures-nmpa-clinical-trial-approval-for-mrna-mpox-vaccine-first-dual-approved-candidate-globally","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68830","title":{"rendered":"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ab&amp;B Bio-Tech Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2627:HKG\">HKG: 2627<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>clinical trial approval<\/strong> for its investigational <strong>mRNA mpox vaccine<\/strong>, making it the <strong>world&#8217;s first mRNA-based mpox vaccine candidate<\/strong> to receive regulatory green lights from both the <strong>U.S. FDA<\/strong> and <strong>China&#8217;s Center for Drug Evaluation (CDE)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>mRNA mpox vaccine (investigational)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of mpox infection<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>24 Jun 2026<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>First mRNA mpox vaccine approved for clinical trials in both US and China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-vaccine-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Vaccine Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> mRNA-based vaccine technology<\/li>\n\n\n\n<li><strong>Target:<\/strong> Multiple orthopoxvirus antigens including mpox virus<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Demonstrates <strong>broad-spectrum cross-reactivity<\/strong> against multiple orthopoxviruses (mpox, vaccinia, variola, ectromelia)<\/li>\n\n\n\n<li><strong>Comparative Advantage:<\/strong> Generates <strong>significantly higher levels of mpox-neutralizing antibodies<\/strong> compared to China&#8217;s Tian Tan strain (live attenuated smallpox vaccine)<\/li>\n\n\n\n<li><strong>Patient Benefit:<\/strong> Shows <strong>superior immunogenicity<\/strong> versus licensed replication-deficient mpox vaccines overseas, offering enhanced protection for <strong>immunocompromised individuals<\/strong> including those who are HIV-positive<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Ab&amp;B mRNA Vaccine<\/th><th>Tian Tan Strain (China)<\/th><th>Licensed Replication-Deficient Vaccines (Overseas)<\/th><\/tr><\/thead><tbody><tr><td><strong>Neutralizing Antibody Levels<\/strong><\/td><td>Significantly higher<\/td><td>Baseline<\/td><td>Moderate<\/td><\/tr><tr><td><strong>Cross-Reactivity<\/strong><\/td><td>Broad-spectrum against multiple orthopoxviruses<\/td><td>Limited<\/td><td>Narrow<\/td><\/tr><tr><td><strong>Suitability for Immunocompromised<\/strong><\/td><td>High (non-replicating platform)<\/td><td>Contraindicated<\/td><td>Moderate<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable (mRNA platform)<\/td><td>Risk of adverse events<\/td><td>Generally favorable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Preclinical studies demonstrated that Ab&amp;B&#8217;s mRNA vaccine induced substantially higher neutralizing antibody titers while maintaining a favorable safety profile inherent to non-replicating vaccine platforms.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Health Security:<\/strong> With mpox remaining a public health concern following the 2022-2023 global outbreak, next-generation vaccines with improved safety profiles are critical for pandemic preparedness<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> As the first dual-approved mRNA mpox vaccine candidate, Ab&amp;B is positioned to capture significant market share in both Western and Chinese markets<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> The vaccine&#8217;s superior immunogenicity and suitability for immunocompromised populations address key limitations of existing smallpox\/mpox vaccines<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Clinical trials will now proceed to evaluate safety and efficacy in human subjects, with potential accelerated pathways given the public health importance<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062300856_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026062300856_c.\"><\/object><a id=\"wp-block-file--media-fe906b3c-8be0-4916-8be3-c75f3cec2086\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062300856_c.pdf\">2026062300856_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026062300856_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fe906b3c-8be0-4916-8be3-c75f3cec2086\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ab&amp;B Bio-Tech Co., Ltd. (HKG: 2627) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4291,62,4334,12],"class_list":["post-68830","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abb-bio-tech","tag-clinical-trial-approval-initiation","tag-hkg-2627","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ab&amp;B Bio-Tech Co., Ltd. (HKG: 2627) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world&#039;s first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China&#039;s Center for Drug Evaluation (CDE).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68830\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally\" \/>\n<meta property=\"og:description\" content=\"Ab&amp;B Bio-Tech Co., Ltd. (HKG: 2627) announced that China&#039;s National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world&#039;s first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China&#039;s Center for Drug Evaluation (CDE).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68830\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T15:42:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-24T15:42:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68830#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68830\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally\",\"datePublished\":\"2026-06-24T15:42:30+00:00\",\"dateModified\":\"2026-06-24T15:42:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68830\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ab&amp;B Bio-Tech\",\"Clinical trial approval \\\/ initiation\",\"HKG: 2627\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68830#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68830\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68830\",\"name\":\"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-24T15:42:30+00:00\",\"dateModified\":\"2026-06-24T15:42:34+00:00\",\"description\":\"Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world's first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China's Center for Drug Evaluation (CDE).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68830#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68830\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68830#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally - Insight, China&#039;s Pharmaceutical Industry","description":"Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world's first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China's Center for Drug Evaluation (CDE).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68830","og_locale":"en_US","og_type":"article","og_title":"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally","og_description":"Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world's first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China's Center for Drug Evaluation (CDE).","og_url":"https:\/\/flcube.com\/?p=68830","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-24T15:42:30+00:00","article_modified_time":"2026-06-24T15:42:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68830#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68830"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally","datePublished":"2026-06-24T15:42:30+00:00","dateModified":"2026-06-24T15:42:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68830"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ab&amp;B Bio-Tech","Clinical trial approval \/ initiation","HKG: 2627","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68830#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68830","url":"https:\/\/flcube.com\/?p=68830","name":"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-24T15:42:30+00:00","dateModified":"2026-06-24T15:42:34+00:00","description":"Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China's National Medical Products Administration (NMPA) has granted clinical trial approval for its investigational mRNA mpox vaccine, making it the world's first mRNA-based mpox vaccine candidate to receive regulatory green lights from both the U.S. FDA and China's Center for Drug Evaluation (CDE).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68830#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68830"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68830#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ab&amp;B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine \u2013 First Dual-Approved Candidate Globally"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68830"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68830\/revisions"}],"predecessor-version":[{"id":68832,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68830\/revisions\/68832"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}